Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 10, 2001 - Issue 8
Submit an article Journal homepage
37
Views
1
CrossRef citations to date
0
Altmetric
Miscellaneous

New therapies and vaccines for meningococcal disease

Enitan D Carrol
,
Alistair PJ Thomson
&
C Anthony Hart
Pages 1487-1500 | Published online: 24 Feb 2005

Bibliography

  • STEPHENS DS, FARLEY MM: Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev. Infect. Dis. (1991) 13:22–33.
  • CARTWRIGHT KA, JONES DM, SMITHAJ, STUART JM, KACZMARSKI EB, PALMER SR: Influenza A and meningococcal disease. Lancet (1991) 338:554–557.
  • HANEBERG B, TONJUM T, RODAHLK, GEDDE-DAHL TW: Factors preceding the onset of meningococcal disease, with special emphasis on passive smoking, symptoms of ill health. NIPH Ann. (1983) 6:169–173.
  • POOLMAN JT, LEY PAVD, TOMMASSEN J: Surface structures and Secreted Products of Meningococci. In: Merringococcal Disease. Cartwright K (Ed.) Jon Wiley and Sons Ltd, Chichester, England (1995):21–34.
  • BRANDTZAEG P, KIERULF P, GAUSTAD P et al:Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. I Infect. Dis. (1989) 159:195–204.
  • ••Important paper showing correlation between endotoxin levels and disease severity.
  • BRANDTZAEG P, MOLLNES TE, KIERULF P: Complement activation and endotoxin levels in systemic meningococcal disease. j Infect. Dis. (1989) 160:58–65.
  • ••Important paper showing correlation between endotoxin levels and disease severity.
  • BRANDTZAEG P, OVSTEBOO R, KIERULF P: Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease. j Infect. Dis. (1992) 166:650–652.
  • MATHISON JC, TOBIAS PS, WOLFSON E, ULEVITCH RJ: Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. I Immune]. (1992) 149:200–206.
  • COLUCCI M, BALCONI G, LORENZETR et al.: Cultured human endothelial cells generate tissue factor in response to endotoxin. j Gun. Invest. (1983) 71:1893–1896.
  • NAWROTH PP, STERN DM: Modulationof endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. (1986) 163:740–745.
  • SUFFREDINI AF, HARPEL PC, PARRILLO JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl. J. Med. (1989) 320:1165–1172.
  • HAZELZET JA, VAN DER VOORT E, LINDEMANS J, TER HEERDT PG, NEIJENS HJ: Relation between cytokines and routine laboratory data in children with septic shock and purpura. Intensive Care Med. (1994) 20:371–374.
  • BAGGIOLINI, M, WALZ A, KUNKEL SL: Neutrophil-activating peptide-1/ interleukin 8, a novel cytokine that activates neutrophils.j Clin. Invest. (1989) 84:1045–1049.
  • HEINZEL FP, RERKO RM, LING E HAKIMI J, SCHOENHAUT DS: Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect. Immun. (1994) 62:4244–4249.
  • TRINCHIERI G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood (1994) 84:4008–4027.
  • HAZELZET JA, KORNELISSE RE VAN DER POUW KRAAN TC et al.: Interleukin 12 levels during the initial phase of septic shock with purpura in children: relation to severity of disease. Cytolone (1997) 9:711–716.
  • RIORDAN FA, MARZOUK 0, THOMSON AE SILLS JA, HART CA: Proinflammatory and anti-inflammatory cytokines in meningococcal disease. Arch. Dis. Child (1996) 75:453–454.
  • VAN DEUREN M, VAN DER VEN-JONGEKRIJG J, BARTELINK AK, VAN DALEN R, SAUERWEIN RW, VAN DER MEER JW: Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J. Infect. Dis. (1995) 172:433–439.
  • WAAGE A, HALSTENSEN A, ESPEVIK T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 1:355–357.
  • ••Important publication demonstrating association between high TNF levels and poor outcome.
  • WAAGE A, BRANDTZAEG P, HALSTENSEN A, KIERULF P, ESPEVIK T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. (1989) 169:333–338.
  • CASEY LC, BALK RA, BONE RC: Plasmacytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. (1993) 119:771–778.
  • LEVIN M, GALASSINI R, DE MUNTER C AND THE MENINGOCOCCAL STUDY GROUP: Improved survival in children admitted to intensive care with meningococcal disease. Proceedings of the 2nd Annual Meeting of the Royal College of Paediatrics and Child Health. York, England (1998).
  • RIORDAN FAT, THOMSON APJ: Recognition, treatment and complications of meningococcal disease. Paediatr. Drugs (1999) 1:263–282.
  • ZIEGLER EJ, MCCUTCHAN JA, FIERER J et al:Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli N Engl. J. Med. (1982) 307:1225–1230.
  • BAUMGARTNER JD, GLAUSER MP, MCCUTCHAN JA et al.: Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet (1985) 2:59–63.
  • J5 STUDY GROUP: Treatment of severeinfectious purpura in children with human plasma from donors immunized with Escherichia coliJ5: a prospective double-blind study. J. Infect. Dis. (1992) 165:695–701.
  • ZIEGLER EJ, FISHER CJ JR, SPRUNGCL et al.: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl. J. Med. (1991) 324:429–436.
  • MCCLOSKEY, RV, STRAUBE RC, SANDERS C, SMITH SM, SMITH CR: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann. Intern. Med. (1994) 121:1–5.
  • DERX B, WITTES J, MCCLOSKEY R: Randomized, placebo-controlled trial of HA-1A, a monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial study Group. Chu Infect Dis (1999) 28:770–777.
  • WEISS J, ELSBACH P, SHU C et al: Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J. Gin Invest. (1992) 90:1122–1130.
  • ••One of the earliest publicationsdemonstrating bactericidal effects of BPI.
  • GAZZANO-SANTORO H, PARENT JB, GRINNA L et al: High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun. (1992) 60:4754–4761.
  • LAMBERT L, WONG P, HOPPE P: Recombinant bactericidal/permeability-increasing (rBPI) protein kills both gram-positive and gram-negative bacteria. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Orlando, Florida (1994).
  • GIROIR BP, QUINT PA, BARTON P et al.: Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet (1997) 350:1439–1443.
  • LEVIN M, QUINT PA, GOLDSTEIN B etal.: Recombinant bactericidal/ permeability-increasing protein (rBPI 21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet (2000) 356:961–967.
  • ••Important publication reporting results ofthe first large multicentre trial of BPi in severe meningococcal sepsis.
  • CHOW JC, YOUNG DW, GOLENBOCK DT, CHRIST WJ, GUSOVSKY F: Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. (1999) 274:10689–10692.
  • WILLIAMS MJ, RODRIGUEZ A, KIMBRELL DA, ELDON ED: The 18-wheeler mutation reveals complex antibacterial gene regulation in Drosophila host defense. EMBO J. (1997) 16:6120–6130.
  • BUNNELL E, LYNN M, HABET K et at.: A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crk Care Med. (2000) 28:2713–2720.
  • KENNEDY NJ, DUNCAN AW: Acute meningococcaemia: recent advances in management (with particular reference to children). Arraesth. Intensive Care (1996) 24:197–216.
  • ••Excellent review of pathophysiology andmanagement of acute meningococcaemia.
  • ESMON CT: The roles of protein C and thrombomodulin in the regulation of blood coagulation. I Biol. Chem. (1989) 264:4743–4746.
  • TAYLOR F, CHANG A, FERRELL G et al.: C4b-binding protein exacerbates the host response to Escherichia coli. Blood (1991) 78:357–363.
  • GRINNELL BW, HERMANN RB, YAN SB: Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Clycobiology (1994) 4:221–225.
  • GREY ST, TSUCHIDA A, HAU H, ORTHNER CL, SALEM HH, HANCOCK WW: Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.j ImmurroL (1994) 153:3664–3672.
  • LECLERC E HAZELZET J, JUDE B et al.: Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med. (1992) 18:202–205.
  • •Publication describing relationship between protein C and S concentrations and outcome.
  • RIVARD GE, DAVID M, FARRELL C, SCHWARZ HP: Treatment of purpura fulminans in meningococcemia with protein C concentrate.j Pediam (1995) 126:646–652.
  • SMITH OP, WHITE B, VAUGHAN D et al.: Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet (1997) 350:1590–1593.
  • FAUST SN, HEYDERMAN RS et al.: Molecular mechanisms of thrombosis in meningococcal septicaemia: the role of the protein C pathway in vivo. Proceedings of the 5th world congress on Trauma, Shock, Inflammation and Sepsis. Munich 2000. Shock (2000) 13:29.
  • BERNARD GR, VINCENT J-L, LATERRE P-F et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N ErigL I Med. (2001) 344:699–709.
  • PILCHER L, HRUBY E, SCHWARZ HP: Attenuation of the Schwartzman reaction in rabbits by activated protein C. Thromb. Haemostat. (1991) 65:1205.
  • FOURRIER F, LESTAVEL P, CHOPIN C eta].: Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med. (1990) 16:121–124.
  • FOURRIER F, CHOPIN C, HUART JJ, RUNGE I, CARON C, GOUDEMAND J: Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest (1993) 104:882–888.
  • FOURRIER F, JOURDAIN M, TOURNOYS A: Clinical trial results with antithrombin III in sepsis. Grit. Care Med. (2000)28(9 suppl):538–543.
  • KUPPERMANN N, INKELIS SH, SALADINO R: The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans. Pediatr. Infect. Dis. J. (1994) 13:867–873.
  • TANAKA Y, ADAMS DH, SHAW S: Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. ImmurroL Today (1993) 14:111–115.
  • HEYDERMAN RS, KLEIN NJ, SHENNAN GI, LEVIN M: Reduction of the anticoagulant activity of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: evaluation by an amidolytic assay. Thromb. Res. (1992) 67:677–685.
  • DU TOIT HJ, COETZEE AR, CHALTON DO: Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon. Crk Care Med. (1991) 19:1195–200.
  • ATTANASIO M, GORI AM, GIUSTI Bet al.: Cytokine gene expression in human LPS- and IFNgamma-stimulated mononuclear cells is inhibited by heparin. Thromb. Haemost. (1998) 79:959–962.
  • BAINES, PB, THOMSON APJ, SILLS JA, RIORDAN FAI, HART CA: A retrospective review of the use of prostacyclin in severe meningococcal sepsis. Pediatr. Rev. Commun. (1996) 8:187.
  • BIHARI DJ, TINKER J: The therapeuticvalue of vasodilator prostaglandins in multiple organ failure associated with sepsis. Intensive Cafe Med. (1988) 15: 2–7.
  • HEYDERMAN, RS, KLEIN NJ, SHENNAN GI, LEVIN M: Deficiency of prostacyclin production in meningococcal shock. Arch. Dis. Child (1991) 66:1296–1299.
  • VOSS R, MATTHIAS FR, BORKOWSKI G, REITZ D: Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br I HaematoL (1990) 75:99–105.
  • HAZELZET JA, RISSEEUW-APPEL IM, KORNELISSE RF etal.: Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb. Haemost. (1996) 76:932–938.
  • KORNELISSE RF, HAZELZET JA, SAVELKOUL HF: The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. I Infect. Dis. (1996) 173:1148–1156.
  • ZENZ, W, BODO Z, ZOBEL G, FANCONI S, RETTENBACHER A: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crk Care Med. (1998) 26:969–973.
  • GUSTO: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl. I Med. (1993) 329:1615–1622.
  • AIUTO LT, BARONE SR, COHEN PS, BOXER RA: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. CriL Care Med. (1997) 25:1079–1082.
  • PETERS M, KERR S: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. CriL Care Med. (1998) 26:972–973.
  • NADEL S, DE MUNTER C, BRITTO J, HABIBI P, LEVIN M: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. CriL Care Med. (1998) 26:971–973.
  • ZENZ W et al.: Use of tissue plaminogen activator (t-PA) in children with fulminant meningococcaemia- a retrospective multicenter study. Proceedings of the European Soden, of Intensive Care Medicare. Rome, Italy (2000)
  • LEFERING R, NEUGEBAUER EAM: Steroid controversy in sepsis and septic shock:A meta-analysis. Grit. Care Med. (1995) 23:1294–1303.
  • BOLLAERT PE, CHARPENTIER C, LEVY B, DEBOUVERIE M, AUDIBERT G, LARCAN A: Reversal of late septic shock with supraphysiological doses of hydrocortisone. Crit Care Med. (1998) 26:645–650.
  • BRIEGEL J, FORST H, HALLER M, SCHELLING G, KILGER E, KUPRAT G et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective randomized, double-blind, single-center study. Crit Care Med. (1999) 27:723–732.
  • POLLACK M: Blood exchange and plasmapheresis in sepsis and septic shock. Clin. Infect. Dis. (1992) 15:431–433.
  • GARDLUND B, SJOLIN J, NILSSON A et al.: Plasmapheresis in the treatment of primary septic shock in humans. Land. Infect. Dis. (1993) 25:757–761.
  • VAN DEUREN M, SANTMAN FW, VAN DALEN R, SAUERWEIN RW, SPAN LF, VAN DER MEER JW: Plasma and whole blood exchange in meningococcal sepsis. Clin. Infect. Dis. (1992) 15:424–430.
  • SCHETZ M: Removal of cytokines in septic patients using continuous veno-venous hemodiafiltration. Grit. Care Med. (1994) 22:715–721.
  • REEVES JH, BUTT WW, SHANN F et al.: Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Grit. Care Med. (1999) 27:2096–2104.
  • BELLOMO R, TIPPING P, BOYCE N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit. Care Med. (1993) 21:522–526.
  • REEVES JH, BUTT WW: Blood filtration in children with severe sepsis: safe adjunctive therapy. Intensive Care Med. (1995) 21: 500–504.
  • BECA J, BUTT W: Extracorporeal membrane oxygenation for refractory septic shock in children. Pediatrics (1994) 93:726–729.
  • CHAMPION MP, MURDOCH IA, SAJJANHAR T, MARSH MJ: Extracorporeal membrane oxygenation for refractory shock in fulminant meningococcal sepsis. Lancet (1996) 347:201–202.
  • GOLDMAN AP KERR SJ, BUTT W et al.: Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet (1997) 349:466–469.
  • 'MACEY KJ, FONG Y, HESSE DG etal.: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1987) 330:662–664.
  • HINSHAW LB, TEKAMP-OLSON P, CHANG AC et al.: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ. Shock (1990) 30:279–292.
  • ABRAHAM E, WUNDERINK R, SILVERMAN H etal.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA (1995) 273:934–941.
  • •Publication describing the results of one of the first large trials of anti-TNF therapy.
  • COHEN J, CARLET J: INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Grit. Care Med. (1996) 24:1431–1440.
  • ABRAHAM E, ANZUETO A, GUTIERREZ G et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (1998) 351:929–933.
  • CLARK MA, PLANK LD, CONNOLLY AB etal.: Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis: a randomized, clinical trial. Grit. Care Med. (1998) 26:1650–1659.
  • FISHER CJ, JR, AGOSTI JM, OPAL SM et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl. J. Med. (1996) 334:1697–1702.
  • ABRAHAM E, GLAUSER MP, BUTLER T etal.: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45–2081 Study Group. JAMA (1997) 277:1531–1538.
  • FISHER CJ, JR, DHAINAUT JF, OPALSM etal.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-lra Sepsis Syndrome Study Group. JAMA (1994) 271:1836–1843.
  • PREAS HL, 2ND, REDA D, TROPEA M etal.: Effects of recombinant soluble Type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood (1996) 88:2465–2472.
  • OPAL SM, FISHER CJ, JR, DHAINAUT JF et al.: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Grit. Care Med. (1997) 25:115–124.
  • CARROL ED, THOMSON AP MOBBS KJ, HART CA: The role of RANTES in meningococcal disease. J. Infect. Dis. (2000) 182:363–366.
  • ANGGARD E: Nitric oxide: mediator, murderer, and medicine. Lancet (1994) 343:1199–1206.
  • BRADY AJ, WARREN JB, POOLE-WILSON PA, WILLIAMS TJ, HARDING SE: Nitric oxide attenuates cardiac myocyte contraction. Am.j Physiol (1993) 265:H176–82.
  • BAINES PB, STANFORD S, BISHOP-BAILEY D et al: Nitric oxide production in meningococcal disease is directly related to disease severity. Grit. Care Med. (1999) 27:1187–1190.
  • •Important publication demonstrating relationship between severity of disease and NO production.
  • SCHOONOVER LL, STEWART AS, CLIFTON GD: Hemodynamic and cardiovascular effects of nitric oxide modulation in the therapy of septic shock. Pharrnacotherapy (2000) 20:1184–1197.
  • SUNDRANI R, EASINGTON CR, MATTOO A, PARRILLO JE, HOLLENBERG SM: Nitric oxide synthase inhibition increases venular leukocyte rolling and adhesion in septic rats. Grit. Care Med. (2000) 28:2898–2903.
  • PRIVALLE C, TALARICO T, KENG T, DEANGELO J: Pyridoxalated hemoglobin polyoxyethylene: a nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock. Free Radic Biol. Med. (2000) 28:1507-1517. ma GOLD R, LEPOW ML, GOLDSCHNEIDER I, DRAPER TL, GOTSCHLICH EC: Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. an. Invest. (1975) 56:1536–1547.
  • LEACH A, 'IVVUMASI PA, KUMAH S et al.: Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide- protein conjugate vaccine. J. Infect. Dis. (1997) 175:200–204.
  • CDSC: Vaccination programme for group C meningococcal infection is launched. Commun. Dis. Rep. CDR Wkly (1999) 9:261,264.
  • RAMSAY M, ANDREWS N, KACZMARSKI EB, MILLER E: Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet (2001) 357:195–196.
  • RICHMOND E BORROW R, MILLER E et al.: Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. (1999) 179:1569–1572.
  • ••Key publication demonstrating efficacy ofmeningococcal C conjugate vaccine in infancy.
  • FAIRLEY CK, BEGG N, BORROW R, FOX AJ, JONES DM, CARTWRIGHT K: Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. (1996) 174:1360-1363. los. 'IVVUMASI PA, JR, KUMAH S, LEACH A et al.: A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. (1995) 171:632–638.
  • GRIFFISS JM, YAMASAKI R, ESTABROOK M, KIM JJ: Meningococcal molecular mimicry and the search for an ideal vaccine. Trans. R. Soc. Trap. Med. Hyg. (1991) 85:32–36.
  • MAKELA, PH: Serum antibodies and bacterial meningitis. Trans. R. Sac. Trap. Med. Hyg. (1991) 85:19-22. los. DE MORAES JC, PERKINS BA, CAMARGO MC et al: Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet (1992) 340:1074–1078.
  • TAPPERO JW, LAGOS R, BALLESTEROS AM et al.: Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 281:1520–1527.
  • CARTWRIGHT K, MORRIS R, RUMKE H etal.: Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine (1999) 17:2612–2619.
  • FUKASAWA LO, GORLA MC, SCHENKMAN RP et al: Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine (1999) 17:2951–2958.
  • ACHTMAN M, NEIBERT M, CROWE BA et al.: Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A. J. Exp. Med. (1988) 168:507–525.
  • ROSENQVIST E, HOIBY EA, WEDEGE E, KUSECEK B, ACHTMAN M: The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. (1993) 167:1065–1073.
  • VIRJI M, MAKEPEACE K, FERGUSON DJ, ACHTMAN M, SARKARI J, MOXON ER: Expression of the Opc protein correlates with invasion of epithelial and endothelial cells by Neisseria meningitidis. Mol. Microbial. (1992) 6:2785–2795.
  • AL'ALDEEN AA, CARTWRIGHT KA: Neisseria meningitidis vaccines and vaccine candidates. j Infect. (1996) 33:153–157.
  • SCHRYVERS AB, LEE BC: Comparative analysis of the transferrin and lactoferrin binding proteins in the family Neisseriaceae. Can. J. Microbial. (1989) 35:409–415.
  • ALA'ALDEEN DA, POWELL NB, WALL RA, BORRIELLO SP: Localization of the meningococcal receptors for human transferrin. Infect. bran= (1993) 61:751–759.

Patents

  • OPHIDIAN PHARM INC.: U55545721 (1996). zoz. XOMA CORP.: U55952302 (1996).
  • ELI LILLY & CO.: US6008199 (1999).
  • BOEHRINGER MANNHEIM GMBH: U55723122 (1998). zos. BASF AS: U55231024 (1993). zos. FONDDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR: W09933989 (1999).
  • SOCIETE DE CONSEILS RECHERCHES ET D'APPLICATIONSSCIENTIFIQUES: U555972940 (1999). zos. CHIRON CORP.: W09961053 (1999). zos. MICROBIOLOGICAL RES AUTHORITY CAMR: W00025811 (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.